🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

9+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 9 of 9 recruiting trials for “Adult T-cell leukemia/lymphoma

Phase 1RecruitingNCT07388563

Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

👨‍⚕️ Max J Gordon, M.D., National Cancer Institute (NCI)📍 1 site📅 Started Mar 2026View details ↗
Phase 2RecruitingNCT07159620

Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients

🏥 The First Affiliated Hospital of Soochow University📍 1 site📅 Started Sep 2025View details ↗
Phase 1RecruitingNCT07108868

A Phase I Dose Finding Study of MB-CART2219.1

🏥 University Hospital Tuebingen📍 2 sites📅 Started Jun 2025View details ↗
Phase 2RecruitingNCT06698003

A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1

👨‍⚕️ Steven Horwitz, MD, Memorial Sloan Kettering Cancer Center📍 7 sites📅 Started Nov 2024View details ↗
Phase 1, PHASE2RecruitingNCT06420076

Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells

🏥 Essen Biotech📍 1 site📅 Started Jul 2024View details ↗
Phase 1, PHASE2RecruitingNCT07075328

A Phase I/II Study of OJP-001 in Patients With Adult T-cell Leukemia/Lymphoma

🏥 Otsuka Medical Devices Co., Ltd. Japan📍 4 sites📅 Started Apr 2024View details ↗
RecruitingNCT06131801

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

👨‍⚕️ Lauren Pommert, MD, Children's Hospital Medical Center, Cincinnati📍 5 sites📅 Started Nov 2023View details ↗
RecruitingNCT05978141

A Registry for People With T-cell Lymphoma

👨‍⚕️ Steven Horwitz, MD, Memorial Sloan Kettering Cancer Center📍 26 sites📅 Started Jul 2023View details ↗
Phase 1RecruitingNCT04848064

Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma

👨‍⚕️ John C Reneau, MD, PhD, Ohio State University Comprehensive Cancer Center📍 1 site📅 Started May 2022View details ↗

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →